Schedule 13G ownership disclosure

Trevi Therapeutics Inc

Common Stock, $0.001 par value per share · CUSIP: 89532M101

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • VIKING GLOBAL INVESTORS LP

    Shares: 9,190,486 · Class: 8.7%

  • Viking Global Opportunities Parent GP LLC

    Shares: 9,190,486 · Class: 8.7%

  • Viking Global Opportunities GP LLC

    Shares: 6,157,625 · Class: 5.8%

  • Viking Global Opportunities Portfolio GP LLC

    Shares: 6,157,625 · Class: 5.8%

  • Viking Global Opportunities Illiquid Investments Sub-Master LP

    Shares: 6,157,625 · Class: 5.8%

  • Viking Global Opportunities Drawdown GP LLC

    Shares: 3,032,861 · Class: 2.9%

  • Viking Global Opportunities Drawdown Portfolio GP LLC

    Shares: 3,032,861 · Class: 2.9%

  • Viking Global Opportunities Drawdown (Aggregator) LP

    Shares: 3,032,861 · Class: 2.9%

  • HALVORSEN OLE ANDREAS

    Shares: 9,190,486 · Class: 8.7%

  • Ott David C.

    Shares: 9,190,486 · Class: 8.7%

  • Shabet Rose Sharon

    Shares: 9,190,486 · Class: 8.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000905148-25-001760
Form type
SCHEDULE 13G/A
Filer
Trevi Therapeutics, Inc.
CIK
CIK 1563880
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub